THU0119 SUCCESSFUL PSYCHOPHARMACOTHERAPY OF ANXIETY AND DEPRESSIVE DISORDERS IMPROVES RHEUMATOID ARTHRITIS REMISSION RATE AT FIVE YEARS FOLLOW-UP

Background Anxiety and depressive disorders (ADD) affect rheumatoid arthritis (RA) disease activity and remission rate. Psychopharmacotherapy (PPT) of ADD attempts to improve the remission rate. Objectives To determine factors associated with RA remission rate. Methods 128 RA-patients (pts) were enrolled, 86% were women with a mean age of 47,4±11,3 (M±SD) yrs. All pts met the full ACR criteria for RA. Remission was defined as DAS28 Results At 5-yrs endpoint in 83 RA-pts remission rate was 22,9% (8,3%, 34,5%, 19,0% and 33,3% in groups 1, 2, 3 and 4, respectively). Significantly higher proportion of patients achieved remission in cDMARDs + PPT group vs cDMARDs group (34,5% vs 8,3%, RR 1,8 (95%CI 0,35 – 9,2), p=0,024). By univariate logistic regression, male sex, younger age, shorter RA duration, RF and ACPA negativity, lower baseline DAS28 and HAQ, absence of extraarticular RA manifestations and depression at the beginning of the study, and remission of anxiety and depressive symptoms at the end of the study were significantly associated with RA remission (table 1). These variables were subjected to multivariate stepwise logistic regression. Only lower baseline DAS28 (OR 0,636 (95%CI 0,515 – 0,785), p Conclusion Lower baseline DAS28 and remission of anxiety and depressive symptoms at 5-yrs endpoint are associated with higher rheumatoid arthritis remission rate at five years follow-up. Disclosure of Interests None declared